Mind the Graph. Foregone Health Gains in Lung Cancer

As thoracic medical oncologists treating patients with Anaplastic Lymphoma Kinase (ALK)-rearranged lung cancer in Australia and New Zealand, we read with interest the efforts of Evans et al [1] to benchmark funded cancer treatments between our two countries. The authors focussed on Progression Free Survival (PFS) and Overall Survival (OS) with application of ASCO-CRC targets and only included therapies with a comparator treatment available in New Zealand. We concur with the critique of methodology published in response by Zalcberg and Wonder [2] and would like to specifically address conclusions made in the setting of ALK-rearranged Non Small Cell Lung Cancer (NSCLC).

Source: Seminars in Oncology - December 2, 2017 Category: Cancer & Oncology Authors: Laird Cameron, Richard Sullivan, Brendan Luey, Ben Solomon Source Type: research